Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Over 50 listed companies including Sun Pharma, Mphasis, Pfizer, Veedol, Dr Reddy's Laboratories have announced final ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

In a market where mega-cap growth and tech stocks continue to dominate headlines and stretch valuations, income-oriented investors may feel sidelined. But for those with a long-term perspective ...

Listen and subscribe to Stocks In Translation on Apple Podcasts, Spotify, or wherever you find your favorite podcast.Nvidia’s (NVDA) explosive growth is doing more than lifting portfolios - it’s ...

This was the stock's third consecutive day of losses.

This was the stock's second consecutive day of losses.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...